DOCSLIB.ORG

Effect of Targeted Polymyxin B Hemoperfusion On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Targeted Polymyxin B Hemoperfusion On SPECTRAL DIAGNOSTICS SDI-PMX-NA001 EUPHRATES TRIAL Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock This confidential document is the property of Spectral Diagnostics and it is provided for the use of the investigator and other designated personnel solely in connection with the conduct of the study described herein. No information contained herein may be disclosed, except as necessary to obtain consent from persons who are considering participation in the study, without prior written approval of Spectral Diagnostics. Current Version: 9.1 Date: 11Aug2015 Spectral Diagnostics (US) Inc. 20201 Century Boulevard, Germantown, MD 20874 Tel301. 528-7000. Fax: 301.528.2300 www.spectraldx.com Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock Protocol Number: SDI-PMX-NA001 Protocol Version: Version 9.1 Date: 11August2015 Medical Monitor: Shide Badri, MD Amarex, LLC 20201 Century Boulevard Germantown, MD USA 20874 Phone: 240-454-6825 Fax: 240-813-2868 Email: [email protected] Sponsor: Spectral Diagnostics (US), Inc. 20201 Century Boulevard, Ste 450 Germantown, MD USA 20874 Phone: 301-528-7000 Fax: 301-528-2300 Previous Protocol Versions: Version 1, July 30, 2009 Version 2, October 30, 2009 Version 3, December 30, 2009 Version 4, January 30, 2010 Version 5, July 1, 2011 Version 6, January 1, 2012 Version 7, April 27, 2012(not distributed to sites) Version 7.1, June 26, 2012 Version 8, August 8, 2012 Version 9, April 28, 2014 2 | Page CONFIDENTIAL Version 9.1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 1 Protocol Synopsis Study Title: Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock. Study Number and Acronym: SDI-PMX-NA001 EUPHRATES Primary Objectives: To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge, versus subjects who receive standard medical care alone. Secondary Objectives: 1. To compare mortality between the two groups at 90 days, 6 months and 12 months post-start of treatment 2. To compare the change in endotoxin levels between the PMX cartridge treated group and the control group at 12 hours after completion of a second PMX cartridge, with a treatment target of a > 15% reduction of EAA levels with PMX cartridge treatment 3. To compare the changes in vasopressor doses for the two groups from Day 0 to Day 3 4. To compare the number of days of need for vasopressors in each group from Day 0 to Day 28 (days alive and off vasopressors) 5. To compare changes in mean arterial blood pressure (MAP) for the two groups from Day 0 to Day 3 6. Comparison of the changes in renal function from day 0 to Day 3: i. Urine output ii. Serum creatinine 7. To compare the effects of two uses of the PMX cartridge on progression of, and recovery from, organ dysfunction using the Multiple Organ Dysfunction Score (MODS) from Day 0 to Day 3 8. To compare the number of days of need for renal replacement therapy (RRT) in each group from Day 0 to Day 28 (days alive and off RRT) 9. To compare the number of days of need for mechanical ventilation (MV) in each group from Day 0 to Day 28 (days alive and off MV) 3 | Page CONFIDENTIAL Version 9.1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 10. To compare the mean number of days spent in the hospital by subjects in each group for survivors to Day 28 11. To compare survival time from baseline to death within 28 days and compare the risk of death between the two study arms 12. To compare survival time from baseline to death within 90 days and compare the risk of death between the two study arms Study Phase: Phase III Number of Centers: Approximately 60 in the USA and Canada Number of Subjects: Approximately 478 (239 per treatment arm) Study Design: Double-blinded, randomized, controlled trial of standard care plus the PMX cartridge versus standard of care alone. Investigational Device: The TORAYMYXIN PMX-20R (PMX cartridge) is a single use extracorporeal hemoperfusion device to remove endotoxin from patients’ blood through direct hemoperfusion (DHP). The PMX cartridge was approved for use in Japan in 1993, in the EU in 1998 and in Canada in 2003. Treatment Intervention: Two (2) PMX cartridges will be administered approximately 24 hours apart. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute). The treatment and control arm of the study will include standard medical care for septic shock which will include fluid replacement, vasopressor infusion, antimicrobials and ventilator support or renal replacement therapy if necessary. Patient Population: Intensive Care Unit subjects with septic shock and endotoxemia. 4 | Page CONFIDENTIAL Version 9.1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 Inclusion Criteria: Subjects who meet the following criteria (and have a signed informed consent) will be allowed into the study: 1. Age ≥18 years of age 2. Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours* a. Norepinephrine > 0.05mcg/kg/min b. Dopamine > 10 mcg/kg/min c. Phenylephrine > 0.4 mcg/kg/min d. Epinephrine > 0.05 mcg/kg/min e. Vasopressin > 0.03 units/min f. Vasopressin (any dose) in combination with another vasopressor listed above 3. The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility 4. Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration 5. Endotoxin Activity Assay ≥ 0.60 EAA units 6. Evidence of at least 1 of the following criteria for new onset organ dysfunction that is considered to be due to the acute illness a. Requirement for positive pressure ventilation via an endotracheal tube or tracheostomy tube b. Thrombocytopenia defined as acute onset of platelet count < 150,000 μ/L or a reduction of 50% from prior known levels c. Acute oliguria defined as urine output < 0.5 ml/kg/hr for at least 6 hours despite adequate fluid resuscitation Exclusion Criteria: 1. Inability to obtain an informed consent from the subject, family member or an authorized surrogate * When determining the eligible dose of vasopressors for a subject whose measured body weight is >100 kg, the maximum weight of 100 kg (220 lbs) will be used. This maximum weight applies to both males and females. 5 | Page CONFIDENTIAL Version 9.1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 2. Lack of commitment for full medical support 3. Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation 4. Subject has end stage renal disease and requires chronic dialysis 5. There is clinical support for non-septic shock such as a. Acute pulmonary embolus b. Transfusion reaction c. Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction < 35%) * 6. Subject has had chest compressions as part of CPR this hospitalization without immediate return to communicative state 7. Subject has had an acute myocardial infarction (AMI) within the past 4 weeks 8. Subject has uncontrolled hemorrhage (acute blood loss requiring > 3 UPC in the past 24 hours) 9. Major trauma within 36 hours of screening 10. Subject has severe granulocytopenia (leukocyte count less than 500 cells/mm3) or severe thrombocytopenia (platelet count less than 30,000 cells/mm3) 11. HIV infection in association with a last known or suspected CD4 count of <50/mm3 12. Subject’s baseline state is non-communicative 13. Subject has sustained extensive third-degree burns within the past 7 days 14. Body weight < 35 kg (77 pounds) 15. Known hypersensitivity to Polymyxin B 16. Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia (H.I.T.) 17. Subject is currently enrolled in an investigational drug or device trial 18. Subject has been previously enrolled in the current trial 19. Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end stage chronic illness with no reasonable expectation of survival to hospital discharge 20. Subject has a screening MOD score ≤9 * Please note that an ejection fraction of <35% does not automatically exclude the subject. This ejection fraction example is intended to describe chronic severe congestive heart failure NYHA Class IV only. 6 | Page CONFIDENTIAL Version 9.1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 EUPHRATES Trial: SDI-PMX-NA001 11Aug2015 Study Procedures: This is a double-blind, randomized, controlled trial of standard medical care plus the PMX cartridge versus standard medical care alone in subjects with endotoxemia and septic shock. Subjects in ICUs will be assessed for septic shock using known or suspected infection and hypotension requiring vasopressor support as primary criteria. Subjects will meet all entry criteria for study except EAA activity ≥ 0.60. Subjects (or surrogate decision maker) will then be consented to a blood draw to determine the presence of an elevated endotoxin level (≥ 0.60 EAA units) using the Endotoxin Activity Assay (EAA™).
Load more

Recommended publications
  • Management of Acute Clonidine Poisoning in Adults: the Role of Resin Hemoperfusion
    Management of Acute Clonidine Poisoning in Adults: The Role of Resin Hemoperfusion Shanshan Fang Department of Nephrology, 307 Hospital Bo Han Department of Nephrology, 307 Hospital Xiaoling Liu Department of Nephrology, 307 Hospital Dan Mao Department of Nephrology, 307 Hospital Chengwen Sun Laboratory of Poisonous Substance Detection, 307 Hospital Zhi Chen Department of Nephrology, 307 Hospital Ruimiao Wang Department of Nephrology, 307 Hospital Xishan Xiong ( [email protected] ) Aliated Hengsheng Hospital of the Southern Medical University https://orcid.org/0000-0002-8557- 8025 Methodology Keywords: clonidine poisoning, adrenergic alpha-agonists, bradycardia, hemoperfusion, hypotension Posted Date: September 21st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-76660/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Clonidine poisoning in adults is rare. An observational retrospective study including 102 adults with clonidine poisoning was conducted. 57 patients with relatively mild conditions were placed in the local emergency departments (EDs) for clinical observation, while the remaining 45 were transferred to the tertiary hospital for intensive treatment, of whom 9 were given supportive care only and 36 were given hemoperfusion (HP), as well as similar supportive treatment. The main symptoms of these cases were: sleepiness, dizziness, fatigue, headache, inarticulacy, tinnitus and dry mouth. Physical examination showed hypotension, bradycardia and shallow and slow breathing. Serum and urine clonidine concentrations were signicantly elevated24.4 ng/ml, 313.2 ng/ml, respectively. All cases slowly returned to their baseline state over 48 to 96 hours, which is co-related with the drawn of serum clonidine level.
    [Show full text]
  • Effect of Hemoperfusion Using Polymyxin B-Immobilized Fiber on IL-6, HMGB-1, and IFN Gamma in a Neonatal Sepsis Model
    0031-3998/05/5802-0309 PEDIATRIC RESEARCH Vol. 58, No. 2, 2005 Copyright © 2005 International Pediatric Research Foundation, Inc. Printed in U.S.A. Effect of Hemoperfusion Using Polymyxin B-Immobilized Fiber on IL-6, HMGB-1, and IFN Gamma in a Neonatal Sepsis Model MOHAMED HAMED HUSSEIN, TAKENORI KATO, TAKAHIRO SUGIURA, GHADA A. DAOUD, SATOSHI SUZUKI, SUMIO FUKUDA, HISANORI SOBAJIMA, INEKO KATO, AND HAJIME TOGARI Department of Pediatrics, Neonatology and Congenital Disorders [M.H.H., T.K., T.S., G.A.D., S.F., H.S., I.K., H.T.], Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Department of Pediatrics [S.S.], Nagoya City Johoku Hospital, Nagoya, Japan, Neonatal Intensive Care Unit [M.H.H.], Pediatric Hospital, Cairo University, Cairo, Egypt, Maternal and Child Health Department [M.H.H., G.A.D.], VACSERA, Giza, Egypt ABSTRACT To evaluate effects of polymyxin B direct hemoperfusion at 6 h. IFN-␥ was only detected in the control group at 9 h. (PMX-DHP) on a neonatal sepsis cecal ligation and perforation Survival times in the PMX-DHP group were longer than in the (CLP) model, in 24 anesthetized and mechanically ventilated control. Thus, PMX-DHP improved septic shock in a neonatal 3-d-old piglets, 16 were assigned to CLP and an arteriovenous septic model. (Pediatr Res 58: 309–314, 2005) extracorporeal circuit from 3 h until 6 h post-CLP, with a PMX-column in PMX-DHP–treated group (8 piglets) and 8 as sham. Plasma lipopolysaccharide (LPS) was measured at before Abbreviations CLP and at 3 and 9 h.
    [Show full text]
  • Uremic Toxins and Blood Purification: a Review of Current Evidence and Future Perspectives
    toxins Review Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives Stefania Magnani * and Mauro Atti Aferetica S.r.l, Via Spartaco 10, 40138 Bologna (BO), Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0535-640261 Abstract: Accumulation of uremic toxins represents one of the major contributors to the rapid progression of chronic kidney disease (CKD), especially in patients with end-stage renal disease that are undergoing dialysis treatment. In particular, protein-bound uremic toxins (PBUTs) seem to have an important key pathophysiologic role in CKD, inducing various cardiovascular complications. The removal of uremic toxins from the blood with dialytic techniques represents a proved approach to limit the CKD-related complications. However, conventional dialysis mainly focuses on the removal of water-soluble compounds of low and middle molecular weight, whereas PBTUs are strongly protein-bound, thus not efficiently eliminated. Therefore, over the years, dialysis techniques have been adapted by improving membranes structures or using combined strategies to maximize PBTUs removal and eventually prevent CKD-related complications. Recent findings showed that adsorption-based extracorporeal techniques, in addition to conventional dialysis treatment, may effectively adsorb a significant amount of PBTUs during the course of the sessions. This review is focused on the analysis of the current state of the art for blood purification strategies in order to highlight their potentialities and limits and identify the most feasible solution to improve toxins removal effectiveness, exploring possible future strategies and applications, such as the study of a synergic approach by reducing PBTUs production and increasing their blood clearance.
    [Show full text]
  • Fluvoxamine Maleate Tablets Safely and Effectively
    Highlights Of Prescribing Information hypotension or seizures (5.7). Methadone: Coadministration may produce These highlights do not include all the information needed to use opioid intoxication. Discontinuation of fluvoxamine may produce opioid Fluvoxamine Maleate Tablets safely and effectively. See full prescribing withdrawal (5.7). Mexiletine: Monitor serum mexiletine levels (5.7). information for Fluvoxamine Maleate Tablets. Ramelteon: Should not be used in combination with fluvoxamine (5.7). Theophylline: Clearance decreased; reduce theophylline dose by one-third Fluvoxamine Maleate Tablets for oral administration (5.7). Warfarin: Plasma concentrations increased and prothrombin times Initial U.S. Approval: 1994 prolonged; monitor prothrombin time and adjust warfarin dose accordingly Warning: Suicidality and Antidepressants (5.7). Other Drugs Affecting Hemostasis: Increased risk of bleeding with See full prescribing information for complete boxed warning. concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation (5.7, Increased risk of suicidal thinking and behavior in children, adolescents, and 5.9). See Contraindications (4). Discontinuation: Symptoms associated with young adults taking antidepressants for major depressive disorder and other discontinuation have been reported (5.8). Abrupt discontinuation not psychiatric disorders. Fluvoxamine Maleate Tablets are not approved for use in recommended. See Dosage And Administration (2.8). pediatric patients except those with obsessive compulsive disorder (5.1). Activation
    [Show full text]
  • Study Protocol for a Randomized
    The Efficacy of Initial Hemopurification Strategy for Acute Paraquat Poisoning in Adults: Study Protocol for a Randomized Controlled Trial (HeSAPP) 2018-4-6 NCT03314909 PROTOCOL Study setting Patient recruitment would be completed in The First Affiliated Hospital of Zhengzhou University, a comprehensive tertiary medical center in Henan Province, China with 50 beds in emergency intensive care units (EICU). The estimated number of admitted acute paraquat poisoned patients ranges from 50-200 persons per year. To assist participant enrolment, after acceptance of this protocol, a notice of this trial would be sent to the Emergency Room (ER) of all secondary hospitals in Henan Province to improve transference to the First Affiliated Hospital of Zhengzhou University. Considering the fact that intervention would be administered in ER setting, and the relatively short duration of assigned hemopurification, adherence of patients is promising. Patients’ families would receive full explanation of treatment plan and continuous follow-up in order to promote adherence. Study population Upon admission to ER, patients suspected with PQ intoxication would receive a urine dithionite test, and only those with a positive result would be invited to participate in this trial. The urine dithionite test would be measured by Spectrophotometer Type 721, and the minimal measurable concentration of paraquat is 0.2 μg/ml. Detailed inclusion and exclusion criteria are listed as follows. Inclusion criteria Patients meeting with all of the following criteria would be included in this trial: (1) Suspected paraquat ingestion history (intended or accidental), which is confirmed by positive urine dithionite result (light blue, navy blue and dark blue). (2) Arriving at the ER within 24 hours after PQ digestion.
    [Show full text]
  • Bhopal Disaster
    Bhopal disaster From Wikipedia, the free encyclopedia Jump to: navigation, search Bhopal memorial for those killed and disabled by the 1984 toxic gas release. The Bhopal disaster also known as Bhopal Gas Tragedy was a gas leak accident in India, considered one of the world's worst industrial catastrophes.[1] It occurred on the night of December 2–3, 1984 at the Union Carbide India Limited (UCIL) pesticide plant in Bhopal, Madhya Pradesh, India. A leak of methyl isocyanate gas and other chemicals from the plant resulted in the exposure of hundreds of thousands of people. Estimates vary on the death toll. The official immediate death toll was 2,259 and the government of Madhya Pradesh has confirmed a total of 3,787 deaths related to the gas release.[2] Others estimate 3,000 died within weeks and another 8,000 have since died from gas-related diseases.[3][4] A government affidavit in 2006 stated the leak caused 558,125 injuries including 38,478 temporary partial and approximately 3,900 severely and permanently disabling injuries.[5] UCIL was the Indian subsidiary of Union Carbide Corporation (UCC). Indian Government controlled banks and the Indian public held 49.1 percent ownership share. In 1994, the Supreme Court of India allowed UCC to sell its 50.9 percent share. Union Carbide sold UCIL, the Bhopal plant operator, to Eveready Industries India Limited in 1994. The Bhopal plant was later sold to McLeod Russel (India) Ltd. Dow Chemical Company purchased UCC in 2001. Civil and criminal cases are pending in the United States District Court, Manhattan and the District Court of Bhopal, India, involving UCC, UCIL employees, and Warren Anderson, UCC CEO at the time of the disaster.[6][7] In June 2010, seven ex-employees, including the former UCIL chairman, were convicted in Bhopal of causing death by negligence and sentenced to two years imprisonment and a fine of about $2,000 each, the maximum punishment allowed by law.
    [Show full text]
  • Escitalopram Oxalate
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------WARNINGS AND PRECAUTIONS------------­ These highlights do not include all the information Clinical Worsening/Suicide Risk: Monitor for clinical needed to use Lexapro® safely and effectively. See full worsening, suicidality and unusual change in behavior, prescribing information for Lexapro®. especially, during the initial few months of therapy or at times of dose changes (5.1). Lexapro® (escitalopram oxalate) Tablets Serotonin Syndrome: Serotonin syndrome has been Lexapro® (escitalopram oxalate) Oral Solution reported with SSRIs and SNRIs, including Lexapro, both Initial U.S. Approval: 2002 when taken alone, but especially when co-administered WARNING: Suicidality and Antidepressant Drugs with other serotonergic agents (including triptans, See full prescribing information for complete boxed tricyclic antidepressants, fentanyl, lithium, tramadol, warning. tryptophan, buspirone, amphetamines, and St. John’s Increased risk of suicidal thinking and behavior in Wort). If such symptoms occur, discontinue Lexapro and children, adolescents and young adults taking initiate supportive treatment. If concomitant use of antidepressants for major depressive disorder (MDD) Lexapro with other serotonergic drugs is clinically and other psychiatric disorders. Lexapro is not warranted, patients should be made aware of a potential approved for use in pediatric patients less than 12 increased risk for serotonin syndrome, particularly during years of age (5.1). treatment initiation and dose increases (5.2). Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is -------------------RECENT MAJOR CHANGES---------------- recommended whenever possible (5.3). Warnings and Precautions (5.2) 1/2017 Seizures: Prescribe with care in patients with a history of seizure (5.4). --------------INDICATIONS AND USAGE------------------- Activation of Mania/Hypomania: Use cautiously in Lexapro® is a selective serotonin reuptake inhibitor (SSRI) patients with a history of mania (5.5).
    [Show full text]
  • Learning Objectives
    Society of Toxicology—Undergraduate Toxicology Course Learning Objectives Approved by SOT Council November 2018 These Learning Objectives were created by the Learning Objectives Work Group, a group appointed by the Education Committee with the charge of creating a guide to facilitate the creation or modification of undergraduate courses in toxicology. The group includes Joshua Gray (chair), Chris Curran, Vanessa Fitsanakis, Sid Ray, and Karen Stine with significant contributions from Betty Eidemiller. The objectives were modeled after the Core Concepts of the Vision and Change report and are aligned with similar Core Concepts which have been developed for 14 other life science courses by their professional scientific societies and which are published atCourseSource . The Learning Objectives were developed following an analysis of undergraduate toxicology syllabi submitted to the SOT’s teaching resource collection as well as an analysis of undergraduate toxicology texts of all genres. Design and Usage: The Level One Objectives build on the foundation of the five Core Concepts first developed for Undergraduate Biology by Vision and Change and used in the subsequent development of objectives for courses such as Biochemistry and Molecular Biology. Level Two Objectives are broad disciplinary categories, beneath which Level Three Objectives discuss particular learning goals. Level Four Objectives are examples of how the Level Three Objectives might be taught and are not intended to be comprehensive. Many Level Four Objectives also include selected case studies and associated articles, as well as links to a case study’s website, PubMed unique identifier (PMID) or PubMed Central reference number (PMCID) that might be useful in teaching an objective.
    [Show full text]
  • National Kidney Foundation K/DOQI Clinical Practice Guidelines for Bone
    The Official Journal of the National Kidney Foundation American Journal of Kidney Diseases AJKDEditorial correspondence and manuscript submis- The appearance of the code at the bottom of the first sions should be addressed to Bertram L. Kasiske, MD, page of an article in this journal indicates the copyright Editor-in-Chief, AJKD, Hennepin Faculty Associates, owner’s consent that copies of the article may be made for 600 HFA Building, Room D508, 914 South 8th Street, personal or internal use, or for the personal or in- Minneapolis, MN 55404. Telephone: (612) 347-7770 ternal use of specific clients. This consent is given on the Business correspondence (subscriptions, change condition, however, that the copier pay the stated per-copy of address) should be addressed to the Publisher, fee through the Copyright Clearance Center, Inc (222 W.B. Saunders, Periodicals Department, 6277 Sea Rosewood Dr, Danvers, MA 01923; (978) 750-8400) for Harbor Dr, Orlando, FL 32887-4800. E-mail: elspcs@ copying beyond that permitted by Sections 107 or 108 of elsevier.com the US Copyright Law. This consent does not extend to Change of address notices, including both the old and other kinds of copying, such as copying for general distri- new addresses of the subscriber, should be sent at least one bution, for advertising or promotional purposes, for creat- month in advance. ing new collective works, or for resale. Absence of the code Customer Service: 1-800-654-2452; outside the United indicates that the material may not be processed through States and Canada, 1-407-345-4000. the Copyright Clearance Center, Inc.
    [Show full text]
  • Clinical Toxicology J.A
    Postgrad Med J: first published as 10.1136/pgmj.69.807.19 on 1 January 1993. Downloaded from Postgrad Med J (1993) 69, 19 - 32 A) The Fellowship of Postgraduate Medicine, 1993 Reviews in Medicine Clinical toxicology J.A. Vale Director, National Poisons Information Service (Birmingham Centre), West Midlands Poisons Unit and Pesticide Monitoring Unit, Dudley Road Hospital, Birmingham B18 7QH, UK Introduction Selfpoisoning is the second most common cause of Much of the relevant literature relates to studies in acute medical presentation to hospital in the UK. volunteers given either a non-toxic marker or a However, as a result ofchanges over the last decade non-toxic dose ofa drug. As a result, the extrapola- both in the amount and type of agent ingested, the tion of many of these data to the poisoned patient majority of patients now suffer little if any adverse cannot be done with confidence. consequence and so require no active medical intervention. Nonetheless, a substantial minority Gastric lavage ofpoisoned patients do still require skilled medical management, often using the facilities of an inten- Although 'the idea of washing out the stomach sive care unit, if they are to survive without any with a syringe and tube, in cases where large important sequelae. Supportive therapy, including quantities oflaudanum and other poisons had been the correction of metabolic abnormalities, is of swallowed,' was first reported by Physick' in 1812 paramount importance in the care of such severely the value of gastric lavage remains controversial. by copyright. poisoned patients and this approach alone has Lavage performed 60 minutes after a therapeutic reduced the mortality significantly.
    [Show full text]
  • Does Hemoperfusion Increase Survival in Acute Paraquat Poisoning? a Retrospective Multicenter Study
    toxics Article Does Hemoperfusion Increase Survival in Acute Paraquat Poisoning? A Retrospective Multicenter Study Ying-Tse Yeh 1,2 , Chun-Kuei Chen 3,4, Chih-Chuan Lin 3,4 , Chia-Ming Chang 2,5, Kai-Ping Lan 5,6 , Chorng-Kuang How 2,5 , Hung-Tsang Yen 2,5 and Yen-Chia Chen 2,5,7,* 1 Department of Emergency Medicine, Taipei Veterans General Hospital Yu Li Branch, Hualien 981, Taiwan; [email protected] 2 Department of Emergency Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan; [email protected] (C.-M.C.); [email protected] (C.-K.H.); [email protected] (H.-T.Y.) 3 Department of Emergency Medicine, Chang Gung Memorial Hospital, Linkou branch, Taoyuan 333, Taiwan; [email protected] (C.-K.C.); [email protected] (C.-C.L.) 4 College of Medicine, Chang Gung University, Taoyuan 333, Taiwan 5 Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan; [email protected] 6 Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan 7 National Defense Medical Center, Emergency Department, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-28757628 Received: 14 September 2020; Accepted: 7 October 2020; Published: 10 October 2020 Abstract: The efficacy of hemoperfusion (HP) in patients with acute paraquat poisoning (PQ) remains controversial. We conducted a multi-center retrospective study to include acute PQ-poisoned patients admitted to two tertiary medical centers between 2005 and 2015. We used the Severity Index of Paraquat Poisoning (SIPP) to stratify the severity of PQ-poisoned patients. The indication to start HP was a positive result for the semiquantitative urine PQ test and presentation to the hospital was within 24 h.
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD January 2015 CONTENTS General Toxicology 8 Metals 38 Management 20 Pesticides 41 Drugs 22 Chemical Warfare 43 Chemical Incidents & 30 Plants 44 Pollution Chemicals 33 Animals 44 CURRENT AWARENESS PAPERS OF THE MONTH Pediatric fatality review of the 2013 National Poison Database System (NPDS): focus on intent Lowry JA, Fine JS, Calello DP, Marcus SM. Clin Toxicol 2015; online early: doi: 10.3109/15563650.2014.996292: While rare, pediatric poisoning fatalities represent a unique group of cases with circumstances and substances that often differ significantly from adult poisonings. For the past several years, a team of pediatric toxicologists has reviewed all the fatal pediatric poisonings reported to poison centers nationwide through the National Poison Database System (NPDS) system. This is the fourth consecutive annual review presented in conjunction with the AAPCC Annual Report. The team evaluated poisoning fatality cases for children and teenagers less than 20 years of age that were reported between January and December 2013. In the past, the team only evaluated cases for those less than 18 years of age. While the total numbers we reviewed this year are included for completeness, this commentary will concentrate on those less than 18 years for consistency with prior reports. Full text available from: http://dx.doi.org/10.3109/15563650.2014.996292 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
    [Show full text]